RT Journal Article
T1 Statement on the translocation potential by Pseudomonas chlororaphis MA342 in plants after seed treatment of cereals and peas and assessment of the risk to humans.
A1 EFSA Panel on Plant Protection Products and their Residues (PPR), 
A1 Hernandez-Jerez, Antonio F
A1 Adriaanse, Paulien
A1 Aldrich, Annette
A1 Berny, Philippe
A1 Coja, Tamara
A1 Duquesne, Sabine
A1 Marinovich, Marina
A1 Millet, Maurice
A1 Pelkonen, Olavi
A1 Pieper, Silvia
A1 Tiktak, Aaldrik
A1 Topping, Christopher J
A1 Wolterink, Gerrit
A1 Herman, Lieve
A1 Chiusolo, Arianna
A1 Magrans, José Oriol
A1 Widenfalk, Anneli
K1 DDR
K1 Pseudomonas chlororaphis MA342
K1 aneugenicity
K1 cereals
K1 genotoxicity
K1 human risk assessment
K1 metabolite
K1 peas
K1 seed treatment
K1 translocation
AB The European Commission requested EFSA to provide scientific advice on the translocation potential by Pseudomonas chlororaphis MA342 in plants after seed treatment of cereals and peas and, if applicable, for a revision of the assessment of the risk to humans by its metabolite 2,3-deepoxy-2,3-didehydro-rhizoxin (DDR) and this based on the evidence available in the dossier for renewal of the approval. The information from other P. chlororaphis strains than MA342 was taken into account with care, because the studies available in the dossier did not confirm the identity of the strain MA342 as belonging to the species P. chlororaphis. It has been concluded that there is a potential for translocation of P. chlororaphis MA342 to edible plant parts following seed treatment till an estimated concentration up to about 105 cfu/g and some exposure can be assumed by consumption of fresh commodities. Also, production of the metabolite DDR in the plant cannot be excluded. Regarding levels of DDR in the raw agricultural commodities, exposure estimates based on the limit of quantification (LOQ) for DDR in cereals cannot be further refined while there is no information on the levels of DDR in peas in the dossier. As regards genotoxicity, DDR induced chromosomal damage; however, it was not possible to conclude whether it is through an aneugenic or clastogenic mechanism. Hence, it is not possible to draw a reliable conclusion that DDR is producing an aneugenic effect nor to determine a threshold dose for aneugenicity. Thus, it is not possible to revise the human risk assessment as regards exposure to DDR. The concerns identified in the EFSA conclusion of 2017 remain.
YR 2020
FD 2020-10-24
LK https://hdl.handle.net/10668/26735
UL https://hdl.handle.net/10668/26735
LA en
DS RISalud
RD Apr 17, 2025